An investigator-sponsored physician-initiated study of RE-024 for the treatment of pantothenate kinase-associated neurodegeneration

Trial Profile

An investigator-sponsored physician-initiated study of RE-024 for the treatment of pantothenate kinase-associated neurodegeneration

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Oct 2017

At a glance

  • Drugs Fosmetpantotenate (Primary)
  • Indications Pantothenate kinase-associated neurodegeneration
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Oct 2017 Results presented in a Retrophin media release.
    • 05 Oct 2017 According to a Retrophin media release, data were presented at the Child Neurology Societys (CNS) 26th Annual Meeting 2017.
    • 23 Jun 2016 Results (n=2) from this trial were presented at the 20th International Congress of Parkinson's Disease and Movement Disorders, according to a Retrophin media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top